Researchers further validated in clinical samples that both EV GPC-3 and CEA could effectively discriminate HCC patients from chronic hepatitis B patients and healthy controls, indicating the enormous potential of these EV proteins as effective biomarkers for early diagnosis of HCC. This evidence concerns the gene GPC3 and chronic hepatitis B virus infection.